Document is current
Any future updates will be listed below
-
Authors
Schally, Andrew V.
Theodoropoulos, George
Sha, Wei
Vidaurre, Irving
Wangpaichitr, Medhi
-
Funding
Funding for this research was provided by:
VA Merit Award (1I01BX005051, 2I01BX004371, 1I01BX005051, 1I01BX005051, 1I01BX005051)
- License Information
-
More Information
Article History
Received: 18 October 2024
Accepted: 29 April 2025
First Online: 23 May 2025
Competing interests
: The Growth Hormone-Releasing Hormone (GH-RH) antagonist (patent no. US8227405B2) was granted for the inhibition of the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers through a direct effect on the cancer cells, and to therapeutic compositions containing these novel peptides and their use.
